Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-2329 tablets, an innovative anti-tumor drug developed by the company [1] Group 1: Product Development - HRS-2329 tablets are designed to treat advanced solid tumors with RAS mutations or amplifications [1] - The drug has shown promising anti-tumor activity in preclinical animal models [1] - Currently, there are no similar drugs approved for sale in both domestic and international markets [1] Group 2: Financial Investment - The total research and development investment for the HRS-2329 project has reached approximately 60.15 million yuan [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年9月30日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）及子公司苏州盛迪 亚生物医药有限公司收到国家药品监督管理局（以下简称"国家药监局"）下发 的《受理通知书》，公司 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-157 江苏恒瑞医药股份有限公司 关于获得药物临床试验批准通知书的公告 本公司董事会及全体董事 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-156 （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年9月30日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生 ...

格隆汇9月30日丨恒瑞医药(01276.HK)发布公告，2025年9月30日耗资人民币69.45万元回购1万股A股， 回购价格每股69.45-69.45元。 ...

智通财经APP讯，恒瑞医药(01276)发布公告，该公司于2025年9月30日斥资69.45万元人民币回购1万股A 股，每股回购价格为69.45元人民币。 ...

公司名稱： 江蘇恒瑞醫藥股份有限公司 呈交日期： 2025年9月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 (註7) (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； (viii) 有關債券、借貸股份、票據或公司債券的信託契約/平邊契據經已製備及簽署，有關詳情已送呈公司註冊處處長存檔（如法律如此規定）。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | ...

Core Insights - The article highlights the top and bottom AH share premium rates as of September 30, with Northeast Electric (00042) leading at 831.03% and Ningde Times (03750) at -15.74% [1][2] Group 1: Top AH Share Premium Rates - Northeast Electric (00042) has a premium rate of 831.03% with a deviation value of 23.88% [2] - Andeli Juice (02218) follows with a premium rate of 225.72% and a deviation value of -4.44% [2] - Zhejiang Shibao (01057) ranks third with a premium rate of 224.28% and a deviation value of 19.52% [2] Group 2: Bottom AH Share Premium Rates - Ningde Times (03750) has the lowest premium rate at -15.74% with a deviation value of -2.42% [2] - Heng Rui Medicine (01276) shows a premium rate of -3.49% and a deviation value of -2.73% [2] - China Merchants Bank (03968) has a premium rate of 3.79% with a deviation value of -2.91% [2] Group 3: Top Deviation Values - Changfei Optical Fiber (06869) leads with a deviation value of 46.77% and a premium rate of 161.18% [2] - Jihong Co., Ltd. (02603) has a deviation value of 28.09% with a premium rate of 47.76% [2] - Dazhong Public Utilities (01635) ranks third with a deviation value of 24.46% and a premium rate of 128.80% [2] Group 4: Bottom Deviation Values - Longyuan Power (00916) has the lowest deviation value at -26.30% with a premium rate of 152.23% [4] - Qin Port Co., Ltd. (03369) follows with a deviation value of -25.11% and a premium rate of 44.48% [4] - Hongye Futures (03678) shows a deviation value of -20.92% with a premium rate of 215.48% [4]

Core Viewpoint - Heng Rui Medicine (01276) experienced a significant stock price increase, with a rise of over 4% at the close, and a current price of HKD 87.95, with a trading volume of HKD 217 million [1] Group 1: Clinical Trials and Approvals - Heng Rui Medicine announced the approval to conduct clinical trials for SHR-7787 injection, SHR-4849 injection, Bevacizumab injection, and Atezolizumab injection [1] Group 2: Licensing Agreement - The company granted Glenmark, an Indian pharmaceutical company, exclusive rights to develop and commercialize its HER2 antibody-drug conjugate, Trastuzumab deruxtecan, in global non-core markets, receiving an upfront payment of USD 18 million and potential milestone payments exceeding USD 1 billion [1] Group 3: Market Rights and Financial Impact - Nomura's report indicates that Heng Rui retains development and commercialization rights for Trastuzumab deruxtecan in major pharmaceutical markets including Greater China, the US, Canada, Europe, and Japan, suggesting that the upfront payment will have a minimal financial impact, but the overall milestone payment scale could be substantial [1] - The collaboration with Glenmark is expected to help unlock the commercial potential of the product, and retaining rights in key markets provides opportunities for larger-scale partnerships in the future [1]

Core Insights - The article highlights significant changes in the stock holdings of various companies under the Hong Kong Stock Connect program, indicating shifts in investor sentiment and potential investment opportunities. Group 1: Stock Increases - Canggang Railway (02169) saw the largest increase in stock holdings, rising by 10.72% to a total holding of 33.06% [1][2] - Goldwind Technology (02208) experienced a 1.17% increase, bringing its holding to 48.64% [1][2] - Zhongchu Innovation (03931) had a 1.02% increase, resulting in a holding of 14.69% [1][2] - The top three companies with the highest increases over the last five trading days were Dazhong Public Utilities (01635) with a 26.45% increase, Canggang Railway (02169) with a 21.07% increase, and Shankao Holdings (00412) with a 12.67% increase [1][3] Group 2: Stock Decreases - Shandong Molong (00568) recorded the largest decrease in stock holdings, dropping by 1.69% to 55.70% [1][2] - Jinli Permanent Magnet (06680) saw a decrease of 1.65%, resulting in a holding of 22.36% [1][2] - Yihua Tong (02402) experienced a 0.89% decrease, bringing its holding to 19.98% [1][2] - Over the last five trading days, the largest decreases were noted for Dongfang Electric (01072) with a 5.93% decrease, Yihua Tong (02402) with a 4.16% decrease, and Ocean Park (02255) with a 2.54% decrease [1][3] Group 3: Long-term Trends - Over the past 20 days, Dazhong Public Utilities (01635) had the highest increase of 27.37%, reaching a holding of 60.02% [4] - Canggang Railway (02169) also saw a significant increase of 21.39%, maintaining a holding of 33.06% [4] - Longfei Optical Fiber and Cable (06869) increased by 17.15%, achieving a holding of 71.17% [4]